Rapport Therapeutics, Inc. RAPP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $107.93M+58.7% | $94.79M+55.6% | $81.73M+47.2% | $74.99M+57.6% | $68M+85.8% | ||
| —— | —— | —— | —— | —— | ||
| $142.21M+52.8% | $125.1M+50.6% | $110.11M+48.1% | $101.77M+63.5% | $93.07M+93.6% | ||
| $142.21M+52.8% | $125.1M+50.6% | $110.11M+48.1% | $101.77M+63.5% | $93.07M+93.6% | ||
| -$122.21M-31.3% | -$125.1M-50.6% | -$110.11M-48.1% | -$101.77M-63.5% | -$93.07M-93.6% | ||
| $14.93M+11.7% | $13.62M+12.2% | $12.41M+24.5% | $13.45M+100% | $13.37M+213% | ||
| $14.93M+11.7% | $13.62M+187% | $12.41M+399% | $13.45M+1,872% | $13.37M+516% | ||
| -$107.28M-34.6% | -$111.48M-42.4% | -$97.7M-36.0% | -$88.31M-40.1% | -$79.7M-55.3% | ||
| -$2.59+13.7% | -$2.85+78.7% | -$2.26+89.6% | -$2.05+92.4% | -$3.00+89.9% | ||
| -$2.59+13.7% | -$2.85+78.7% | -$2.26+89.6% | -$2.05+92.4% | -$3.00+89.9% | ||
| 159.5M+57.1% | 147.6M+116% | 129.4M+164% | 126.3M+702% | 101.5M+1,457% | ||
| 159.5M+57.1% | 147.6M+116% | 129.4M+164% | 126.3M+702% | 101.5M+1,457% | ||
| -$107.69M-35.2% | -$110.42M-40.1% | -$97.96M-37.1% | -$88.21M-39.6% | -$79.64M-54.7% | ||
| -$410K-731% | $1.07M+303% | -$255K-164% | $107K+158% | $65K+140% | ||
| —— | —— | —— | —— | —— | ||
| -$122.21M-31.3% | -$125.1M-50.6% | -$110.11M-48.1% | -$101.77M-63.5% | -$93.07M-93.6% | ||
| -$121.21M-31.5% | -$124.08M-50.9% | -$109.1M-48.0% | -$100.79M-63.0% | -$92.14M— | ||
| -$121.21M-31.5% | -$124.08M-50.9% | -$109.1M-48.0% | -$100.79M-63.0% | -$92.14M— | ||
| -$122.21M-31.3% | -$125.1M-50.6% | -$110.11M-48.1% | -$101.77M-63.5% | -$93.07M-93.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.